Skip to main content

Advertisement

Table 1 Baseline demographics and disease characteristics

From: Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy

  Total baricitinib
(N = 106)
Age, years, mean (SD) 55.1 (11.5)
 < 65 years, n (%) 82 (77)
 ≥ 65 years, n (%) 24 (23)
Female, n (%) 85 (80)
Race, n (%)
 White 89 (84)
 Black/African American 15 (14)
 Asian 1 (1)
 Multiple or other 1 (1)
Duration of RA diagnosis, years, mean (SD) 12.1 (9.3)
MTX use, n (%)
 Without MTX 12 (11)
 MTX-treated 94 (89)
 Weekly dose (mg/week), mean (SD) 18.2 (6.6)
Current corticosteroid use, n (%) 32 (30)
 Daily dose (mg/day), mean (SD) 6.2 (2.7)
Weight, kg, mean (SD) 87.6 (21.7)
Swollen joint count, of 66, mean (SD) 3.7 (4.7)
Tender joint count, of 68, mean (SD) 5.0 (9.0)
hsCRP, mg/L, mean (SD) 9.3 (15.2)
HAQ-DI, mean (SD), (range 0–3) 0.9 (0.6)
DAS28-CRP, mean (SD) (range 2–10) 2.9 (1.1)
CDAI, mean (SD) 8.9 (8.8)
SDAI, mean (SD) 9.9 (8.8)
Physician’s global assessment of disease activity (0–100), mean (SD) 14.2 (14.6)
  1. Demographic and disease characteristics are based on vaccine substudy baseline
  2. CDAI Clinical Disease Activity Index, DAS28 Disease Activity Score 28 Joints, HAQ-DI Health Assessment Questionnaire-Disability Index, hsCRP high-sensitivity C-reactive protein, N number of patients in the safety population, MTX methotrexate, RA rheumatoid arthritis, SD standard deviation, SDAI Simplified Disease Activity Index